NR 565 ADVANCED PHARMACOLOGY CHAMBERLAIN UNIVERSITY (MIDTERM) – QUESTIONS AND ANSWERS |
VERIFIED AND WELL DETAILED ANSWERS | PLUS RATIONALES | GUARANTEED PASS | LATEST EXAM UPDATE
Core Domains
1. Pharmacokinetics and Pharmacodynamics
2. Autonomic Nervous System Pharmacology
3. Cardiovascular and Renal Pharmacology
4. Central Nervous System Pharmacology
5. Endocrine and Metabolic Pharmacology
6. Anti-inflammatory, Immunomodulatory, and Antimicrobial Agents
7. Pharmacogenomics and Personalized Medicine
8. Legal, Ethical, and Prescriptive Authority Considerations in Advanced Practice Nursing
Introduction
This comprehensive examination is designed to assess the advanced practice nursing student's mastery of core
pharmacological principles essential for safe and effective prescriptive practice. The assessment evaluates foundational
knowledge of drug actions, clinical application in managing common and complex health conditions, and critical
decision-making skills in diverse patient scenarios. Through a rigorous multiple-choice format, including clinical case
studies, students are challenged to integrate pharmacotherapeutic knowledge with patient-specific factors, regulatory
guidelines, and ethical considerations. Success on this examination reflects readiness for the advanced pharmacology
competencies required in graduate nursing education and clinical practice.
SECTION ONE: QUESTIONS 1 – 100
1. A 72-year-old patient with heart failure is prescribed a new medication. Which pharmacokinetic change
associated with aging most significantly increases the risk of adverse drug effects?
,A. Increased renal clearance of water-soluble drugs
B. Decreased hepatic blood flow and reduced first-pass metabolism
C. Increased gastric pH and delayed gastric emptying
D. Increased total body water and decreased body fat
🟢 B. Decreased hepatic blood flow and reduced first-pass metabolism
🔴 Explanation: Aging is associated with a reduction in hepatic blood flow and liver mass, which decreases first-pass
metabolism. This leads to higher bioavailability of orally administered drugs, increasing the risk of toxicity. While
other changes occur, the reduction in hepatic metabolism is a major factor in adverse drug effects in the elderly.
2. A patient is prescribed a drug that is a weak acid with a pKa of 4.5. In which physiological environment would
this drug be most rapidly absorbed from the gastrointestinal tract?
A. The stomach (pH 1.5)
B. The duodenum (pH 6.0)
C. The jejunum (pH 7.0)
D. The ileum (pH 7.5)
🟢 A. The stomach (pH 1.5)
🔴 Explanation: Weak acids are primarily non-ionized (lipophilic) at pH levels below their pKa, facilitating passive
diffusion across lipid membranes. At a gastric pH of 1.5, which is well below the pKa of 4.5, the drug will be
predominantly non-ionized, promoting rapid absorption in the stomach.
3. A patient with renal impairment is receiving a drug that is primarily eliminated by the kidneys. Which
adjustment is most appropriate to maintain therapeutic drug levels while minimizing toxicity?
,A. Administer a loading dose and reduce the maintenance dose.
B. Administer a larger loading dose and increase the maintenance dose interval.
C. Administer a standard loading dose and reduce the maintenance dose.
D. Administer a reduced loading dose and increase the maintenance dose.
🟢 C. Administer a standard loading dose and reduce the maintenance dose.
🔴 Explanation: In renal impairment, the maintenance dose should be reduced to prevent drug accumulation and
toxicity, as clearance is decreased. The loading dose is primarily determined by the volume of distribution and is
generally unchanged, while the maintenance dose and dosing interval are adjusted based on the patient's renal
function.
4. A prescriber is considering a drug regimen for a patient with a genetic polymorphism that results in decreased
CYP2D6 activity. What is the most likely consequence of this genetic variation?
A. Increased clearance of prodrugs that require CYP2D6 for activation
B. Decreased risk of drug-drug interactions
C. Increased therapeutic effect of drugs metabolized by CYP2D6
D. Decreased risk of adverse effects from drugs metabolized by CYP2D6
🟢 A. Increased clearance of prodrugs that require CYP2D6 for activation
🔴 Explanation: CYP2D6 is a key enzyme in drug metabolism. Decreased activity due to a polymorphism (poor
metabolizer phenotype) will lead to reduced activation of prodrugs (e.g., codeine to morphine), resulting in lower
plasma concentrations of the active metabolite and potentially reduced therapeutic effect. Conversely, it can
increase the risk of toxicity for drugs that are inactivated by CYP2D6.
5. A patient develops a strong, productive cough after starting lisinopril. What is the most likely underlying
mechanism?
, A. Activation of bradykinin and substance P
B. Increased production of angiotensin II
C. Direct stimulation of the cough center in the medulla
D. Bronchoconstriction due to beta-2 receptor blockade
🟢 A. Activation of bradykinin and substance P
🔴 Explanation: ACE inhibitors like lisinopril prevent the breakdown of bradykinin, leading to its accumulation.
Bradykinin and substance P are potent inflammatory mediators that can cause irritation and a persistent, dry, or
productive cough. This is a class-specific adverse effect.
6. A patient on warfarin therapy is started on amiodarone. Which interaction is most concerning and requires
immediate intervention?
A. Increased risk of gastrointestinal bleeding
B. Increased INR and risk of hemorrhage
C. Decreased INR and risk of thromboembolism
D. Increased risk of hepatotoxicity
🟢 B. Increased INR and risk of hemorrhage
🔴 Explanation: Amiodarone is a potent inhibitor of CYP2C9, the enzyme responsible for metabolizing the more
active S-enantiomer of warfarin. This leads to a significant increase in the INR, markedly raising the patient's risk of
severe bleeding. The INR must be closely monitored and the warfarin dose reduced accordingly.
7. A patient with a history of peptic ulcer disease is prescribed an NSAID for arthritis. Which co-therapy is most
effective at reducing the risk of NSAID-induced gastric ulcers?
VERIFIED AND WELL DETAILED ANSWERS | PLUS RATIONALES | GUARANTEED PASS | LATEST EXAM UPDATE
Core Domains
1. Pharmacokinetics and Pharmacodynamics
2. Autonomic Nervous System Pharmacology
3. Cardiovascular and Renal Pharmacology
4. Central Nervous System Pharmacology
5. Endocrine and Metabolic Pharmacology
6. Anti-inflammatory, Immunomodulatory, and Antimicrobial Agents
7. Pharmacogenomics and Personalized Medicine
8. Legal, Ethical, and Prescriptive Authority Considerations in Advanced Practice Nursing
Introduction
This comprehensive examination is designed to assess the advanced practice nursing student's mastery of core
pharmacological principles essential for safe and effective prescriptive practice. The assessment evaluates foundational
knowledge of drug actions, clinical application in managing common and complex health conditions, and critical
decision-making skills in diverse patient scenarios. Through a rigorous multiple-choice format, including clinical case
studies, students are challenged to integrate pharmacotherapeutic knowledge with patient-specific factors, regulatory
guidelines, and ethical considerations. Success on this examination reflects readiness for the advanced pharmacology
competencies required in graduate nursing education and clinical practice.
SECTION ONE: QUESTIONS 1 – 100
1. A 72-year-old patient with heart failure is prescribed a new medication. Which pharmacokinetic change
associated with aging most significantly increases the risk of adverse drug effects?
,A. Increased renal clearance of water-soluble drugs
B. Decreased hepatic blood flow and reduced first-pass metabolism
C. Increased gastric pH and delayed gastric emptying
D. Increased total body water and decreased body fat
🟢 B. Decreased hepatic blood flow and reduced first-pass metabolism
🔴 Explanation: Aging is associated with a reduction in hepatic blood flow and liver mass, which decreases first-pass
metabolism. This leads to higher bioavailability of orally administered drugs, increasing the risk of toxicity. While
other changes occur, the reduction in hepatic metabolism is a major factor in adverse drug effects in the elderly.
2. A patient is prescribed a drug that is a weak acid with a pKa of 4.5. In which physiological environment would
this drug be most rapidly absorbed from the gastrointestinal tract?
A. The stomach (pH 1.5)
B. The duodenum (pH 6.0)
C. The jejunum (pH 7.0)
D. The ileum (pH 7.5)
🟢 A. The stomach (pH 1.5)
🔴 Explanation: Weak acids are primarily non-ionized (lipophilic) at pH levels below their pKa, facilitating passive
diffusion across lipid membranes. At a gastric pH of 1.5, which is well below the pKa of 4.5, the drug will be
predominantly non-ionized, promoting rapid absorption in the stomach.
3. A patient with renal impairment is receiving a drug that is primarily eliminated by the kidneys. Which
adjustment is most appropriate to maintain therapeutic drug levels while minimizing toxicity?
,A. Administer a loading dose and reduce the maintenance dose.
B. Administer a larger loading dose and increase the maintenance dose interval.
C. Administer a standard loading dose and reduce the maintenance dose.
D. Administer a reduced loading dose and increase the maintenance dose.
🟢 C. Administer a standard loading dose and reduce the maintenance dose.
🔴 Explanation: In renal impairment, the maintenance dose should be reduced to prevent drug accumulation and
toxicity, as clearance is decreased. The loading dose is primarily determined by the volume of distribution and is
generally unchanged, while the maintenance dose and dosing interval are adjusted based on the patient's renal
function.
4. A prescriber is considering a drug regimen for a patient with a genetic polymorphism that results in decreased
CYP2D6 activity. What is the most likely consequence of this genetic variation?
A. Increased clearance of prodrugs that require CYP2D6 for activation
B. Decreased risk of drug-drug interactions
C. Increased therapeutic effect of drugs metabolized by CYP2D6
D. Decreased risk of adverse effects from drugs metabolized by CYP2D6
🟢 A. Increased clearance of prodrugs that require CYP2D6 for activation
🔴 Explanation: CYP2D6 is a key enzyme in drug metabolism. Decreased activity due to a polymorphism (poor
metabolizer phenotype) will lead to reduced activation of prodrugs (e.g., codeine to morphine), resulting in lower
plasma concentrations of the active metabolite and potentially reduced therapeutic effect. Conversely, it can
increase the risk of toxicity for drugs that are inactivated by CYP2D6.
5. A patient develops a strong, productive cough after starting lisinopril. What is the most likely underlying
mechanism?
, A. Activation of bradykinin and substance P
B. Increased production of angiotensin II
C. Direct stimulation of the cough center in the medulla
D. Bronchoconstriction due to beta-2 receptor blockade
🟢 A. Activation of bradykinin and substance P
🔴 Explanation: ACE inhibitors like lisinopril prevent the breakdown of bradykinin, leading to its accumulation.
Bradykinin and substance P are potent inflammatory mediators that can cause irritation and a persistent, dry, or
productive cough. This is a class-specific adverse effect.
6. A patient on warfarin therapy is started on amiodarone. Which interaction is most concerning and requires
immediate intervention?
A. Increased risk of gastrointestinal bleeding
B. Increased INR and risk of hemorrhage
C. Decreased INR and risk of thromboembolism
D. Increased risk of hepatotoxicity
🟢 B. Increased INR and risk of hemorrhage
🔴 Explanation: Amiodarone is a potent inhibitor of CYP2C9, the enzyme responsible for metabolizing the more
active S-enantiomer of warfarin. This leads to a significant increase in the INR, markedly raising the patient's risk of
severe bleeding. The INR must be closely monitored and the warfarin dose reduced accordingly.
7. A patient with a history of peptic ulcer disease is prescribed an NSAID for arthritis. Which co-therapy is most
effective at reducing the risk of NSAID-induced gastric ulcers?
